Roche's anti-TIGIT drug suffers a phase III cancer setback

Nat Rev Drug Discov. 2022 May;21(5):327. doi: 10.1038/d41573-022-00068-4.
No abstract available

Publication types

  • News

MeSH terms

  • Drug Industry
  • Humans
  • Neoplasms* / drug therapy